Develops oral drugs for inflammatory bowel diseases.
Jun 2026Revenue $0.50/yrExpenses $35.3M/yr
No trendCash runway ≈ 6.9 years from Jun 2026
Figures by year
When will Palisade Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.50 and expenses $35.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $18.1M | −$18.1M |
| Dec 2024 | $0.00 | $14.9M | −$14.9M |
| Dec 2023 | $300K | $13.4M | −$13.1M |
| Dec 2022 | $0.00 | $15.7M | −$15.7M |
| Dec 2020 | $13.5K | $9.31M | −$9.30M |
| Dec 2019 | $15.4K | $8.65M | −$8.63M |
| Dec 2018 | $260K | $8.52M | −$8.26M |
| Dec 2017 | $260K | $13.6M | −$13.3M |
| Dec 2016 | $16.2K | $20.7M | −$20.6M |
| Dec 2015 | $10.4K | $19.2M | −$19.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.